MedPath

Marker Therapeutics

Marker Therapeutics logo
🇺🇸United States
Ownership
Public
Employees
8
Market Cap
-
Website
http://www.markertherapeutics.com
Introduction

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Clinical Trials

6

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:3
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (50.0%)
Phase 2
3 (50.0%)

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

Phase 1
Recruiting
Conditions
MDS
Acute Myeloid Leukemia, in Relapse
Interventions
First Posted Date
2024-08-14
Last Posted Date
2025-07-15
Lead Sponsor
Marker Therapeutics, Inc.
Target Recruit Count
40
Registration Number
NCT06552416
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

KU Cancer Center, KAnsas city, Kansas, United States

MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Phase 1
Not yet recruiting
Conditions
Pancreas Cancer
First Posted Date
2024-08-12
Last Posted Date
2024-08-12
Lead Sponsor
Marker Therapeutics, Inc.
Target Recruit Count
30
Registration Number
NCT06549751

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

Phase 1
Recruiting
Conditions
Hodgkin Lymphoma
Hodgkin's Lymphoma, Relapsed, Adult
Non Hodgkin Lymphoma
Non-Hodgkin Lymphoma, Adult
Non-Hodgkin Lymphoma, Refractory
Non-Hodgkin Lymphoma, Relapsed
Hodgkin Lymphoma, Adult
Interventions
First Posted Date
2023-04-05
Last Posted Date
2024-05-30
Lead Sponsor
Marker Therapeutics, Inc.
Target Recruit Count
79
Registration Number
NCT05798897
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado, United States

🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

and more 4 locations

Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Phase 2
Completed
Conditions
Acute Myeloid Leukemia
Stem Cell Transplantation
Interventions
First Posted Date
2020-08-13
Last Posted Date
2024-11-20
Lead Sponsor
Marker Therapeutics, Inc.
Target Recruit Count
47
Registration Number
NCT04511130
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

Moores Cancer Center at University of Californa San Diego, La Jolla, California, United States

and more 15 locations

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Phase 2
Terminated
Conditions
Platinum Sensitive Ovarian Cancer
Ovarian Cancer
Interventions
Drug: Adjuvant (GM-CSF) Alone
Biological: FRα peptide plus Adjuvant (GM-CSF)
First Posted Date
2016-11-30
Last Posted Date
2022-12-15
Lead Sponsor
Marker Therapeutics, Inc.
Target Recruit Count
120
Registration Number
NCT02978222
Locations
🇺🇸

UAB Gynecology Oncology, Birmingham, Alabama, United States

🇺🇸

Mayo Clinic Cancer Center, Phoenix, Arizona, United States

🇺🇸

Women's Cancer Research Foundation, Newport Beach, California, United States

and more 15 locations
  • Prev
  • 1
  • 2
  • Next

News

Lymphodepletion Enhances MAR-T Cell Therapy Efficacy in Lymphoma Patients, Marker Therapeutics Reports

Marker Therapeutics' Phase 1 APOLLO study shows lymphodepletion significantly improves expansion and persistence of MT-601 MAR-T cells in lymphoma patients, potentially enhancing anti-tumor activity.

FibroBiologics Opens New Houston Laboratory to Accelerate Fibroblast-Based Therapeutics Development

• FibroBiologics has unveiled a new 10,000-square-foot laboratory facility in Houston that will bring manufacturing operations in-house and accelerate development of fibroblast-based therapeutics for chronic diseases. • The expanded facility will increase the company's research capabilities, reduce reliance on external partners like Charles River Laboratories, and enable FibroBiologics to streamline its supply chain for cell therapy products. • With 240+ patents issued and pending, FibroBiologics plans to hire additional researchers to support its growing pipeline of candidates targeting multiple chronic disease indications using its proprietary fibroblast technology.

Marker Therapeutics' MT-601 Shows 78% Response Rate in Refractory Lymphoma Patients

• Marker Therapeutics' lead MAR-T cell therapy MT-601 (neldaleucel) demonstrated a 78% objective response rate in lymphoma patients who relapsed after anti-CD19 CAR-T therapy, with 44.4% achieving complete responses. • The company secured over $13 million in non-dilutive funding from CPRIT and NIH to support clinical programs for pancreatic cancer and lymphoma, while also raising $16.1 million through a private placement. • MT-601 showed a favorable safety profile with no immune-effector cell associated neurotoxicity syndrome and only one case of Grade 1 cytokine release syndrome reported in the Phase 1 APOLLO trial.

MAGEA4-Targeted Therapies Show Promise in Solid Tumors Beyond Synovial Sarcoma

Afamitresgene autoleucel (afami-cel; Tecelra) received FDA approval for unresectable or metastatic synovial sarcoma, marking the first engineered cell therapy approval for a solid tumor.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.